Malignant Vulvar Neoplasm — Trials

Malignant Vulvar Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

184 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 54
Recruiting: 32
Ph III recruiting: 1
Growth YoY: —
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 21.3%
Trials / 1,000 deaths: 36.6 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (14)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03220009	Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma	withdrawn	Phase 2	0	National Cancer Institute (NCI)NIH	1	Oct 3, 2018	clinicaltrials

Data updated 22 days agoSource updated Oct 3, 2018source: clinicaltrials